Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Verdict

Headline leans bullish. We score 2181.HK +1.00 across four claims.

Score confirms the headline.

Headline says

Leans bullish

From its wording — no explicit rating

=

Expected · 2181.HK

+1.00strongly bullish